Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparison of Efficacy and Safety of Icaritin Versus Sorafenib in First-line Treatment of PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects: a Multicenter, Randomized, Opened Phase III Clinical Trial

NCT03236649 is registered in ClinicalTrials.gov with Beijing Shenogen Biomedical Co., Ltd as lead sponsor.

NCT NCT03236649
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03236649 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparison of Efficacy and Safety of Icaritin Versus Sorafenib in First-line Treatment of PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects: a Multicenter, Randomized, Opened Phase III Clinical Trial
Lead sponsor
Beijing Shenogen Biomedical Co., Ltd
Phase
Phase 3
Overall status
Terminated
Start date
September 20, 2017
Completion date
February 8, 2022
Enrollment
89 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma (hcc)